

Exploring the Role of Anatomical Factors in Female Infertility: A Review

Atul Shrikrishna Dange¹ and Dr. Asgar Khan²

Research Scholar, Department of Bio-Chemistry¹

Assistant Professor, Department of Bio-Chemistry²

Sunrise University, Alwar, Rajasthan, India

Abstract: *The main causes of female infertility include endometriosis, congenital/acquired uterine abnormalities, and post-infectious tubal damage. Septate uterus with myomas and synechiae may cause infertility, miscarriage, and other pregnancy issues. Pelvic inflammatory illness causes most tubal injuries. Surgery may cure tubal factor infertility with reproductive results equivalent to in vitro fertilization. Endometriosis, a common gynecologic condition, may cause pain and infertility in reproductive-age women. Immunological, genetic, and environmental factors may induce endometriosis-related infertility. The condition's cause is unclear. Despite its ubiquity, endometriosis' causes are unknown. Certain medical, surgical, and psychological treatments for endometriosis may enhance quality of life. In most cases, endometriosis surgery increases fertility. Endometriosis and the immune system are linked, therefore future treatments may use immunologic ideas.*

Keywords: Anatomical Causes, Management Strategies, Patient Care

I. INTRODUCTION

Anatomical anomalies: The most prevalent cause of female infertility?

Endometriosis, uterine myomas, congenital uterine malformations, tuboperitoneal abnormalities, and other rare reproductive system anomalies may cause female infertility.

Infertility assessments find tuboperitoneal involvement in 25%–35% of women [1,2]. Pelvic inflammatory disease (PID) causes most tubal damage. Monitoring data shows that 1.7% and 8% of UK and US women between 16 and 46 receive PID diagnoses annually, 15% of Swedish women will receive a diagnosis, and over a million American women receive PID treatment annually. Reports show 12% tubal infertility after one PID episode, 23% after two, and 54% after three. A recent review of 24 articles from the US and Europe found that up to 18% of women in these countries may lose their ability to conceive after showing signs of PID from any source [3]. STIs such Chlamydia trachomatis cause most PID in high-income countries [4]. Because tubal disease is generally asymptomatic, women seldom know they have it unless their medical history is taken. Other causes of tubal damage include postsurgical adhesions and endometriosis (stage III or IV).

Endometriosis affects 5%–15% of fertile women. Even while 20% to 25% of affected women are asymptomatic, the illness may cause pain and infertility. The cause of endometriosis-related infertility is unclear, although a complex interaction of immunological, genetic, and environmental factors is recognized, with mechanical factors prevailing in the late stages.

Miscarriages or infertility due to acquired (myomas and synechiae) or congenital (septate uterus) uterine cavity deformations indicate implantation failure [5]. Congenital uterine anomalies may cause infertility, early labor, poor fetal presentation, and pregnancy loss. Septate uteri, the most common defect, causes pregnancy losses of 60% and fetal survival rates of 6% to 28% [6, 7].

Uterine myomas affect 20%–50% of reproductive-age women. Submucous or intramural myomas hinder spontaneous conception and IVF [8]. Obliterating the uterine cavity with intrauterine synechiae, or adhesions, may induce subfertility and hypomenorrhea or amenorrhea. Synechiae may delay placental tissue removal or need repeated curettages following spontaneous miscarriage in 40% of women [9]. The cause of infertility is sometimes unknown despite all efforts.

Post-infectious tuboperitoneal causes: Current impact of infertility

PTO, periadnexal adhesions, and DTO are post-infectious tubal damage (Fig. 1). Tubal patency testing before fertility therapy is the gold standard for infertile women [10,11]. When skilled, hysterosalpingography or contrast sonography may assess tubal patency in women without PID [11,12]. To avoid unnecessary IVF and embryo transfer, diagnostic laparoscopy should be done when results are abnormal [13]. When endometriosis, periadnexal adhesions, or tubal illness are present, laparoscopy is the preferred method for evaluating tubal factor infertility. Consider laparoscopy ahead of intensive empirical therapies with high costs and hazards [11].

Proximal tubal occlusion

In 10% of tubal diseased women, proximal tubal occlusion develops [12]. A true pathological occlusion from post-infectious fibrosis, an obstruction due to technical artifacts like cervical seal adequacy, intrauterine pressure, uterine-tubal ostium spasm, thick endometrium acting as a valve, or plugs of amorphous material of unknown etiology, often appearing t Between 42% and 95% of women identified with PTO do not have the illness [15,16].

A retrospective research by Al-Jaroudi et al. [16] examined reproductive results in women who had selective tubal catheterization for bilateral PTO. In 98 infertile women with bilateral PTO, a second hysterosalpingography was performed before selective tubal implantation. Twelve women had unilateral tubal patency, while 72 had bilateral PTO. Recanalization of both tubes was accomplished in 25 (34.7%) and at least one tube in 44 (61.1%) of 72 women who had selective tubal catheterization. Follow-up showed 23 conceptions within 24 months.

After 12, 18, and 24 months, the cumulative chance of conception was 28%, 59%, and 73%. Some individuals who failed tubal recanalization may have had a genuine occlusion due to fibrin scarring from salpingitis, endometriosis, or prior surgery. The standard of therapy is microsurgical excision of the occluded tubal part and tubocornual anastomosis of the patent distal tube to the intramural portion. 1, 2, and 3 years following surgery, live birth rates were 27%, 47%, and 53% [17].



Fig. 1. Distal tubal occlusion of the right fallopian tube with mild periadnexal adhesions.

Marana et al. [18] reviewed 9 case series of 187 PTO patients and found a 49% term pregnancy rate and 4% ectopic pregnancy risk following laparotomy. The outcomes are comparable to IVF [10,18].

Periadnexal adhesions

Operative laparoscopy is the best salpingo-ovariolysis method. In non-selected individuals, laparoscopic salpingo-ovariolysis resulted in 51% to 62% intrauterine pregnancy and 5% to 8% ectopic pregnancy [10]. Salpingoscopy, the direct evaluation of the tubal mucosa by a dedicated, small-caliber endoscope during laparoscopy, is the most important prognostic factor for reproductive outcome after salpingo-ovariolysis, according to recent prospective studies. [19–23].

Brosens et al. [20] and Marana et al. [21–23] found that 80% of periadnexal adhesion patients have normal tubal mucosa, 70% will have a term pregnancy after laparoscopic salpingo-ovariolysis, and most pregnancies occur within a

year. Most patients with periadnexal adhesions have retained tubal mucosa, therefore salpingectomy is not needed until hydrosalpinx causes extensive tubal damage.

Distal tubal occlusion

Marana et al. [24] found a 33% cumulative pregnancy rate per patient with microsurgical laparotomic salpingoneostomy in 10 investigations with 1128 participants. The pregnancies were 77% intrauterine, 61% term, 23% ectopic, and 15% spontaneous abortions.

A meta-analysis of 5 nonrandomized controlled trials compared laparotomic microsurgical tubal surgery with laparoscopic DTO therapy [25]. 138 (28.9%) of the 478 laparotomic patients and 104 (30.9%) of the 336 laparoscopic patients had intrauterine pregnancies. No significant difference was seen in intrauterine pregnancy rates between groups. Three trials provided sufficient information to compare surgical procedures at various stages of tubal disease. In the mild tubal disease categories, 83 (32.8%) of 253 laparotomy patients and 96 (39.5%) of 243 laparoscopy patients had intrauterine pregnancies. No significant change was seen in intrauterine pregnancy rates.

According to the Practice Committee of the American Society for Reproductive Medicine [26], surgical DTO therapy for moderate tubal illness (which accounts for 25% of DTO patients) has live birth rates of 39% to 59% and ectopic pregnancy rates of 4% to 10%. Ectopic pregnancy rates are comparable after reconstructive surgery and IVF (4%–10% versus 1%–13%) [26].

Schippert et al. [27,28] examined pregnancy rates in surgically treated women with mild or moderate acquired tubal illness. For salpingoneostomy, adhesiolysis, and tubal sterilization reversal, term pregnancy rates were 65%, 70%, and 80%. Ectopic pregnancy rates varied from 1% to 10% depending on tubal illness, although they were fewer than 10% among women who reversed tubal sterilization. Results after IVF varied from 2.1% to 11%.

In women having salpingoneostomy or salpingo-ovariolysis, the tubal mucosa on salpingoscopy is the most significant predictive indicator for reproductive outcome. Brosens [20] and Marana et al. [21–23] found that 35% to 45% of DTO patients had normal tubal mucosa and 65% will have a term pregnancy following laparoscopic salpingoneostomy. However, salpingectomy may be superior for badly injured tubal mucosa. The authors of this study recently disclosed a simplified salpingoscopy approach for women with DTO, introducing a small-caliber hysteroscope via an auxiliary trocar during laparoscopy [29].

Tubal reconstructive surgery vs IVF

IVF is the main treatment for tubal infertility, however tubal reconstructive surgery is still common. Many couples reject IVF for moral, spiritual, or financial grounds. Remember that surgery cures women with normal tubal mucosa, whereas IVF bypasses tubal injury. These ladies can conceive spontaneously and frequently without medication. They may also undergo pregnancy and delivery like women without tubal infertility, but without the hazards of IVF, such as OHSS, multiple pregnancies, preterm deliveries, and congenital abnormalities. Tubal surgery has little risks, including anesthesia and surgical problems, unlike IVF, which may cause OHSS [30]. Ovulation induction may cause this deadly disease. Intravascular depletion from OHSS may cause hemoconcentration-induced thrombosis, hypovolemia, dehydration, and electrolyte abnormalities. OHSS occurs in 1%–10% of IVF cycles, with 0.25%–2% having severe cases [31].

The 2007 American Society for Reproductive Medicine registry [32] analyzes assisted reproductive technology practices and outcomes since 2001 and shows a 27.2% live birth rate per cycle. In 2010, European statistics showed a clinical pregnancy rate of 29.0% per retrieval [33]. Although the European report lacks data to compute the live birth rate per cycle, a range of 21.0% to 22.5% may be inferred. Italy's latest statistics shows 16.8% live births each cycle [34]. Singleton, twin, and triplet births are 64.1%, 32.0%, and 3.7% in the US and 79.2%, 19.9%, and 0.9% in Europe after IVF. Because of this, the primary difficulty with IVF internationally, compared to spontaneous conception, is still multiple pregnancies, which increase the risk of preterm birth, cesarean delivery, and other complications [14, 35].

Their experiment had significant dropout rates, with 74% after the first unsuccessful effort, 61% after the second, and 69% after the third. This is significant to Sharma et al. [36]'s cumulative IVF pregnancy rates (66% after 4 rounds). Psychological stress and disappointment are the main reasons people quit treatment after many attempts [37].

Recent studies have shown that IVF pregnancies, even singletons, have poor outcomes [38]. Birth abnormalities were 30–40% greater and low birth weight, premature delivery, and perinatal mortality were twice as prevalent as in spontaneously conceived pregnancies [38–49]. A 2010 Danish study [50] evaluated 20,166 singleton pregnancies. After adjusting for mother age, BMI, educational attainment, smoking status, and alcohol/coffee usage during pregnancy, IVF patients had roughly four times the risk of stillbirth compared to spontaneous conceivers.

IVF outcomes are improving, but tubal reconstructive surgery is still a good option for many couples. Surgery should be the initial step in diagnosing and treating tubal infertility. Surgical success depends on proper diagnosis and patient selection.

Endometriosis in the 21st century

Endometriosis contains endometrial glands and stroma outside the uterus [51]. Endometriosis affects 5–15% of reproductive-age women. Endometriosis causes dysmenorrhea, significant dyspareunia, pelvic pain, abnormal uterine bleeding, digestive difficulties, and infertility [51]. Endometriosis is more frequent in women with pelvic pain or infertility (40%–60% vs. 20%–30%) [52]. Laparoscopic endometriosis imaging and histology are the best diagnostic methods [53].

Three hypotheses explain endometriosis: embryonic origin [54], coelomic metaplasia [55], and the commonly recognized retrograde menstruation hypothesis [56], when endometrial pieces develop into the peritoneal cavity. It is unknown how endometriosis causes pain and infertility, although therapies targeting progesterone resistance, systemic immunological dysfunction, angiogenesis, inflammation, neurotropism, and pain transmission, including neuropathic pain, have been suggested [57].

Several authors have explained endometriosis' immunological system [58,59]. Endometrial cell development is promoted by peritoneal macrophage activation, decreased T and NK cell cytotoxicity, increased pro-inflammatory cytokines and growth hormones, and altered cellular immunity. Proliferation, inflammation, and angiogenesis result from these cells [60–63]. Recent study shows adult uterine stem cells, menstrual fluid, and endometrial implants beyond the uterus. Endometriosis may be caused by stem cells [64].

Peritoneal, ovarian, and deep-infiltrating endometriosis [65,66]. Endometriosis may infect the rectovaginal septum, retrocervical region, sigmoid, rectum, ureters, and bladder with lesions beyond 5 mm [67]. Minimal, mild, moderate, and severe are the American Society for Reproductive Medicine [68] classifications.

Cancer antigen 125 from human epithelial carcinoma is the most studied marker. It is a serum marker for endometriosis but has little diagnostic relevance [69,70]. Due to imaging advances, transvaginal ultrasonography is preferable for endometriosis diagnosis [71–73].

Current therapies tackle symptoms, not the disease. Medical, surgical, and psychological treatments may help endometriosis sufferers. Nonsteroidal anti-inflammatory medications, oral contraceptives, gonadotropin-releasing hormone agonists, danazol, and progestins relieve pain [74].

The cause of endometriosis-related infertility is uncertain. Altered folliculogenesis, ovulatory failure, decreased granulosa cell preovulatory steroidogenesis, sperm phagocytosis, poor fertilisation, early embryonic development toxicity, faulty implantation, and oocyte alterations [63]. Cervical stenosis, uterine abnormalities, PTO, DTO, and perimenbrial and peritubal adhesions may cause infertility (75).

Interesting, 50% of conception troubles are caused by male spouses or both. The most important test for male infertility is semen analysis [76].

Endometriosis-related infertility treatment is difficult. Although endometriosis treatment may ease pain, it does not improve infertility. Randomized clinical trials and meta-analyses have demonstrated that medical therapy alone is unsuccessful and that medical therapy with surgery is not better than surgery alone [77,78]. There are no randomized clinical trials comparing non-treatment to surgery for expectant management. Contrary to this technique, some investigations demonstrate very low spontaneous pregnancy rates without medication [78]. Surgery may fix endometriosis-related infertility. Surgery substantially enhanced conception rates in mild endometriosis (stages 1 and 2) patients compared to diagnostic laparoscopy [79]. Surgery is better to expectant care for advanced disease because it may achieve 50% to 67% postoperative pregnancy rates (Fig. 2) without randomized clinical trials [80,81].

Due to the difficulties of randomized study, infertile women with severe endometriosis have no consensus on surgery versus reproductive technology. In the solitary randomized trial, Bianchi et al. [82], surgery outperformed IVF without surgery. Infertility-associated deep endometriosis needs further investigation to identify its importance and treatment options. Darai et al. [83] found that laparoscopy was more likely than laparotomy to promote spontaneous pregnancy in severe colorectal endometriosis.

Congenital and acquired uterine causes

Most female reproductive tract problems are congenital uterine malformations. Incomplete müllerian duct fusion causes problems in 4% of fertile women [7]. Septate, bicornuate, and arcuate uteri predominate [7]. Few unicornuate and didelphys uteri exist.

Uterine anomalies may induce recurring miscarriage, preterm labor, poor fetal presentation, and infertility [6,7]. Although simpler, septate uterus, the most common malformation, has the poorest reproductive results, with pregnancy losses of over 60% and fetal survival rates of 6% to 28% [6].

Incomplete septum, arcuate, bicornuate, and didelphys are the most frequent uterine anomalies. Hysterosalpingography and hysteroscopy may show the interior geometry of a double uterine cavity, but the fundus must be examined to identify problems. Single for septate or arcuate uterus, double for bicornuate or didelphys. Traditionally, laparoscopy and hysteroscopy assessed the uterine exterior. Uterine abnormality diagnosis now uses magnetic resonance imaging and 3-dimensional ultrasonography instead of laparoscopy. Hysteroscopy with intraoperative 3-dimensional ultrasonography may reduce partial uterine septum removal [84].

After two spontaneous abortions, uterine malformation surgery was often advised. As surgery has grown less invasive, prophylactically when no spontaneous abortion has occurred, particularly in women with a septate uterus, and infertility has been related to various uterine anomalies, surgical repair has been done. Surgical hysteroscopy addresses septate and arcuate uteri. Cold scissors or monopolar or bipolar electrosurgery may treat the deformity hysteroscopically with similar results. Post-septum removal term delivery is 75% [7]. Hysteroscopic surgery cannot fix complex abnormalities, which increase reproductive results if untreated. Surgery requires laparotomy.

The most common benign tumors in reproductive-age women are uterine myomas (20–50%) [85]. Submucosal, intramural, and subserosal myomas distort the uterine cavity (Fig. 3) and protrude [86].




Fig. 2. Severe case of endometriosis, with bilateral ovarian-endometriomal adhesions and obliteration of the cul-de-sac.




Fig. 3. Submucosal myoma with bleeding visualized during hysteroscopy.

Myomas can affect fertility through cervix displacement, uterine cavity enlargement, proximal fallopian tube obstruction, altered tubo-ovarian anatomy, uterine contractility, endometrial disruption, impaired blood flow, inflammation, and abnormal vasoactive substance secretion.

The tumors showed uterine myomas' main growth factors. MYOMAS have more estrogen and progesterone receptors, aromatase P450, and estrogen synthetase than the surrounding myometrium depending on the menstrual cycle [88,89]. Many women have asymptomatic uterine myomas. Signs include abnormal uterine bleeding, dysmenorrhea, pelvic pressure, pain, abdominal girth increase, urine or rectal symptoms, and reproductive failure [87]. By analyzing size, quantity, and location, transvaginal ultrasonography may determine whether a myoma should be treated hysteroscopically or abdominally [8,87]. Operative hysteroscopy is best for endometrial submucous myomas. Submucosal and intramural myomas that extend into the endometrial cavity diminish pregnancy and implantation rates but enhance them when removed in retrospective and case-control studies [90–92].

Gonadotropin-releasing hormone analogues before hysteroscopy may improve larger submucous myoma surgery [93]. Laparoscopy or laparotomy treat intraamural, subserous, and plicated myomas, depending on amount and size. When fertility is not an issue and the patient accepts non-conservative treatment, hysterectomy may substitute myomectomy. Intrauterine adhesions might completely block the uterine chamber. This affects 1.5% of infertile women [94]. Low menstrual flow and infertility are the most common symptoms [9,95]. Repeated curettage following abortions and delayed placental tissue removal may cause 40% of synechiae [96]. Diagnostic hysteroscopy detects intrauterine synechiae best [97].

The surgery is hysteroscopic adhesiolysis. Initial adhesion severity influences anatomy, menstruation, and pregnancy [95,97]. 3%–23% of adhesions reoccur, and severe adhesions are 20%–62% [95]. Physical and pharmacological supplements are widespread. These include endometrial estrogen stimulation, intrauterine contraceptive device insertion after surgery, Foley catheter insertion, or newer synthetic barriers that physically separate endometrial cavity walls [9,95,98–100].

Perspectives

Uterine congenital and acquired disorders may cause infertility and pregnancy loss. Diagnostic and treatment advances have improved care for women with uterine infertility. Better candidate selection for reconstructive tubal surgery in tuboperitoneal women may increase intrauterine pregnancy rates to 65%–70%. Complex endometriosis affects infertility management. Fertilization rates rise significantly following surgery. Despite its great incidence and huge physical, psychological, and economic cost, endometriosis' etiology is still unknown. There are evident links between endometriosis and the immune system, thus future treatments may involve immunological.

II. CONCLUSION

Anatomical causes of female infertility, including uterine abnormalities, fallopian tube blockages, and ovarian issues, significantly impact a woman's ability to conceive. Understanding these underlying anatomical factors is crucial for effective diagnosis and management. Advances in medical imaging, such as hysterosalpin gography and laparoscopy, allow for precise identification of these issues, enabling targeted interventions. Management strategies may include surgical correction of anatomical abnormalities, assisted reproductive technologies like in vitro fertilization (IVF), or medications to stimulate ovulation. Addressing these anatomical causes not only enhances reproductive outcomes but also empowers women by providing them with informed choices regarding their fertility journey. Continued research and development of minimally invasive techniques hold promise for improving the management of female infertility and ultimately supporting women's reproductive health.

REFERENCES

- [1]. The Practice Committee of the American Society for Reproductive Medicine. The role of tubal reconstructive surgery in the era of assisted reproductive technologies. *Fertil Steril* 2008;90(3):S250–3.
- [2]. Ahmad G, Watson A, Vandekerckhove P, Lipford R. Techniques for pelvic surgery in subfertility. *Cochrane Database Syst Rev* 2006;2:CD 000221.
- [3]. Haggerty CL, Gottlieb SL, Taylor BD, Low N, Xu F, Ness RB. Risk of sequelae after Chlamydia trachomatis genital infection in women. *J Infect Dis* 2010;201(S2): S134–55.
- [4]. Rodgers AK, Budrys NM, Gong S, Wang J, Holden A, Schenken RS, et al. Genome- wide identification of Chlamydia trachomatis antigens associated with tubal factor infertility. *Fertil Steril* 2011;96(3):715–21.
- [5]. Steinkeler JA, Woodfield CA, Lazarus E, Hillstrom MM. Female infertility: a systematic approach to radiologic imaging and diagnosis. *Radiographics* 2009; 29(5):1353–70.
- [6]. Homer HA, Li TC, Cooke ID. The septate uterus: a review of management and repro- ductive outcome. *Fertil Steril* 2000;73:1–14.
- [7]. Grimbizis GF, Camus M, Tarlatzis BC, Bontis JN, Devroey P. Clinical implications of uterine malformations and hysteroscopic treatment results. *Hum Reprod Update* 2001;7(2):161–74.
- [8]. Olive DL, Pritts EA. Fibroids and reproduction. *Semin Reprod Med* 2010; 28(3):218–27.
- [9]. Thomson AJ, Abbott JA, Deans R, Kingston A, Vancaillie TG. The management of in-traiterine synechiae. *Curr Opin Obstet Gynecol* 2009;21(4):335–41.
- [10]. Gomel V, McComb PF. Microsurgery for tubal infertility. *J Reprod Med* 2006;51(3):177–84.
- [11]. The Practice Committee of the American Society for Reproductive Medicine. Optimal evaluation of the infertile female. *Fertil Steril* 2006;84(3):S264–7.
- [12]. National Institute for Clinical Excellence. Fertility: Assessment and treatment for people with fertility problems. London, UK: RCOG Press; 2004.
- [13]. Tanahatoc S, Lambalk C, McDonnell J, Dekker J, Mijatovic V, Hompes P. Diagnostic laparoscopy is needed after abnormal hysterosalpingography to prevent over- treatment with IVF. *Reprod Biomed Online* 2008;16(3):410–5.
- [14]. Marana R, Ferrari S, Astorri AL, Muzii L. Indications to tubal reconstructive surgery in the era of IVF. *Gynecol Surg* 2008;5:85–91.
- [15]. Marana R, Muzii L, Paielli FV, Lucci FM, Dell'Acqua S, Mancuso S. Proximal tubal ob- struction: are we over-diagnosing and over-treating? *Gynecol Endosc* 1992;1:99–101.
- [16]. Al-Jaroudi D, Herba MJ, Tulandi T. Reproductive performance after selective tubal catheterization. *J Minim Invasive Gynecol* 2005;12:150–2.
- [17]. Patton PE, Williams TJ, Coulam CB. Microsurgical reconstruction of the proximal oviduct. *Fertil Steril* 1987;47:35–9.
- [18]. Marana R, Quagliarello J. Proximal tubal occlusion: microsurgery versus IVF: a review. *Int J Fertil* 1998;33:338–40.
- [19]. Brosens IA, Boek W, Delattin P. Salpingoscopy: a new preoperative diagnostic tool in tubal infertility. *J Obstet Gynecol* 1987;94:768–73.

- [20]. Brosens IA. The value of salpingoscopy in tubal infertility. *J Reprod Med Rev* 1996;5:1–9.
- [21]. Marana R, Rizzi M, Muzii L, Catalano GF, Caruana P, Mancuso S. Correlation between the American Fertility Society classification of adnexal adhesions and distal tubal occlusion, salpingoscopy and reproductive outcome in tubal surgery. *Fertil Steril* 1995;64:924–9.
- [22]. Marana R, Catalano GF, Muzii L, Caruana P, Margutti F, Mancuso S. The prognostic role of salpingoscopy in laparoscopic tubal surgery. *Hum Reprod* 1999;14:2991–5.
- [23]. Marana R, Catalano GF, Muzii L. Salpingoscopy. *Curr Opin Obstet Gynecol* 2003;15:333–6.
- [24]. Marana R, Quagliarello J. Distal tubal occlusion: microsurgery versus IVF: a review. *Int J Fertil* 1998;33:107–15.
- [25]. Ahmad G, Watson AJS, Metwally M. Laparoscopy of laparotomy for distal tubal surgery? A meta-analysis. *Hum Fertil* 2007;10:43–7.
- [26]. The Practice Committee of the American Society for Reproductive Medicine. The role of tubal reconstructive surgery in the era of assisted reproductive technologies. *Fertil Steril* 2008;90(3):S250–3.
- [27]. Schippert C, Garcia Roca GJ. Is there still a role for reconstructive microsurgery in tubal infertility? *Curr Opin Obstet Gynecol* 2011;23:200–5.
- [28]. Schippert C, Soergel P, Staboulidou I, Bassler C, Galalick S, Hillemanns P, et al. The risk of ectopic pregnancy following tubal reconstructive microsurgery and assisted technology procedures. *Arch Gynecol Obstet* 2012;285:863–71.
- [29]. Muzii L, Angioli R, Tambone V, et al. Salpingoscopy during laparoscopy using a small caliber hysteroscope introduced through an accessory trocar. *J Laparoendosc Adv Surg Tech A* 2010;20:619–21.
- [30]. Muzii L, Marana R. Tubal reanastomosis or IVF? *Fertil Steril* 2008;90(1):242–3.
- [31]. Pandian Z, Akande VA, Harrild K, et al. Surgery for tubal infertility. *Cochrane Database Syst Rev* Jul 16 2008(3):CD006415.
- [32]. Society for Assisted Reproductive Technology, American Society for Reproductive Medicine. Assisted reproductive technology in the United States: 2001 results generated from the American Society for Reproductive Medicine/Society for Assisted Reproductive Technology registry. *Fertil Steril* 2007;87:1253–66.
- [33]. de Mouzon J, Goossens V, Bhattacharya S, et al. Assisted reproductive technology in Europe, 2006. Results generated from European registers by ESHRE. *Hum Reprod* 2010;25:1851–62.
- [34]. Ministro della Salute. Relazione al Parlamento sullo stato di attuazione della legge contenente norme in materia di PMA. Attività anno 2009; June 28, 2011. Rome.
- [35]. Marana R, Ferrari A, Merola A, Astorri AL, Pompa G, Milardi D, et al. Il ruolo di un approccio chirurgico mini-invasivo nella diagnosi e trattamento della sterilità tuboperitoneale in alternativa alla FIVET. *Minerva Ginecol* 2010;63:1–10.
- [36]. Sharma V, Allgar V, Rajkhova M. Factors influencing the cumulative conception rate and discontinuation of in vitro fertilization treatment for infertility. *Fertil Steril* 2002;78(1):40–6.
- [37]. Rajkhova M, McConnell A, Thomas GE. Reasons for discontinuation of IVF treatment: a questionnaire study. *Hum Reprod* 2006;21(2):358–63.
- [38]. Kalra SK, Barnhart KT. In vitro fertilization and adverse childhood outcomes: what we know, where we are going, and how we will get there. A glimpse into what lies behind and beckons ahead. *Fertil Steril* 2011;95(6):1887–9.
- [39]. Schieve LA, Ramussen SA, Buck GM, Schendel DE, Reynolds MA, Wright VC. Are children born after assisted reproductive technology at increased risk for adverse health outcomes? *Obstet Gynecol* 2004;103:1154–63.
- [40]. Bower C, Hansen M. Assisted reproductive technologies and birth outcomes: overview of recent systematic reviews. *Reprod Fertil Dev* 2005;17:329–33.
- [41]. McDonald SD, Murphy K, Beyene J, Ohlsson A. Perinatal outcomes of singleton pregnancies achieved by in vitro fertilization: a systematic review and meta-analysis. *Obstet Gynaecol Can* 2005;27:449–59.

- [42]. McDonald SD, Han Z, Mulla S, Murphy KE, Beyene J, Ohlsson A, et al. Preterm birth and low birth weight among in vitro fertilization singletons: a systematic review and meta-analyses. *Eur J Obstet Gynecol Reprod Biol* 2009;146:138–48.
- [43]. Hansen M, Bower C, Milne E, de Klerk N, Kurinczuk JJ. Assisted reproductive technologies and the risk of birth defects- a systematic review. *Hum Reprod* 2005;20:328–38.
- [44]. Klemetti R, Gissler M, Sevón T, Koivurovas S, Rivanen A, Hemminki E. Children born after assisted fertilization have an increased rate of major congenital anomalies. *Fertil Steril* 2005;84:1300–7.
- [45]. Olson CK, Keppler-noreuil KM, Romitti PA, Budelier WT, Ryan G, Sparks AE. In vitro fertilization is associated with an increase in major birth defects. *Fertil Steril* 2005;84(5):1308–15.
- [46]. Allen VM, Wilson RD, Cheung A, Genetics Committee of the Society of Obstetricians and Gynaecologists of Canada (SOGC), Reproductive Endocrinology Infertility Committee of the Society of Obstetricians and Gynaecologists of Canada (SOGC). Pregnancy outcomes after assisted reproductive technology. *J Obstet Gynaecol Can* 2006;28(3):220–50.
- [47]. El-Chaar D, Yang Q, Gao J, Bottomley J, Leader A, Wen SW, et al. Risk of birth defects increased in pregnancies conceived by assisted human reproduction. *Fertil Steril* 2009;92(5):1557–61.
- [48]. Bukulmez O. Does assisted reproductive technology cause birth defects? *Curr Opin Obstet Gynecol* 2009;21(3):260–4.
- [49]. Reefhuis J, Honein MA, Schieve LA, Correa A, Hobbs CA, Rasmussen SA, et al. Assisted reproductive technology and major structural birth defects in the United States. *Hum Reprod* 2009;24(2):360–6.
- [50]. Wisbork K, Ingerslev HJ, Henriksen TB. In vitro fertilization and preterm delivery, low birth weight, and admission to the neonatal intensive care unit: a prospective follow-up study. *Fertil Steril* 2010;94(6):2102–6.
- [51]. Giudice LC, Kao LC. Endometriosis. *Lancet* 2004;364(9447):1789–99.
- [52]. Ajossa S, Mais V, Guerriero S, Paoletti AM, Caffiero A, Murgia C, et al. The prevalence of endometriosis in premenopausal women undergoing gynecological surgery. *Clin Exp Obstet Gynecol* 1994;21(3):195–7.
- [53]. Abrao MS, Neme RM, Carvalho FM, Aldrighi JM, Pinotti JA. Histological classification of endometriosis as a predictor of response to treatment. *Int J Gynaecol Obstet* 2003;82(1):31–40.
- [54]. Batt RE, Smith RA, Buck GM, Severino MF, Naples JD. Müllerianosis. *Prog Clin Biol Res* 1990;323:413–26.
- [55]. Meyer R. On the question of adenomyositis and adenoma in general and specifically on adenomyositis seroepithelialis and adenomyometritis sarcomatosa. *Zentralbl Gynakol* 1919;36:745–59.
- [56]. Sampson JA. Peritoneal endometriosis due to the menstrual dissemination of endometrial tissue into the peritoneal cavity. *Am J Obstet Gynecol* 1927;14:422–69.
- [57]. Giudice LC. Clinical practice. Endometriosis. *N Engl J Med* 2010;362(25):2389–98.
- [58]. Podgaec S, Dias Jr JA, Chapron C, Oliveira RM, Baracat EC, Abrão MS. Th1 and Th2 immune responses related to pelvic endometriosis. *Rev Assoc Med Bras* 2010;56(1):92–8.
- [59]. Herington JL, Bruner-Tran KL, Lucas JA, Osteen KG. Immune interactions in endometriosis. *Expert Rev Clin Immunol* 2011;7(5):611–26.
- [60]. Oral E, Arici A. Pathogenesis of endometriosis. *Obstet Gynecol Clin North Am* 1997;24(2):219–33.
- [61]. Matarese G, De Placido G, Nikas Y, Alviggi C. Pathogenesis of endometriosis: natural immunity dysfunction or autoimmune disease? *Trends Mol Med* 2003;9(5):223–8.
- [62]. Christodoulakos G, Augoulea A, Lambrinouadaki I, Sioulas V, Creatsas G. Pathogenesis of endometriosis: the role of defective 'immunosurveillance'. *Eur J Contracept Reprod Health Care* 2007;12(3):194–202.
- [63]. Halis G, Arici A. Endometriosis and inflammation in infertility. *Ann N Y Acad Sci* 2004;1034:300–15.
- [64]. Figueira PG, Abrão MS, Krikun G, Taylor H. Stem cells in endometrium and their role in the pathogenesis of endometriosis. *Ann N Y Acad Sci* 2011;1221:10–7.
- [65]. Koninckx PR, Martin DC. Deep endometriosis: a consequence of infiltration or retraction or possibly adenomyosis externa? *Fertil Steril* 1992;58(5):924–8.

- [66]. Nisolle M, Donnez J. Peritoneal endometriosis, ovarian endometriosis, and adenomyotic nodules of the rectovaginal septum are three different entities. *Fertil Steril* 1997;68(4):585–96.
- [67]. Cornillie FJ, Oosterlynck D, Lauweryns JM, Koninckx PR. Deeply infiltrating pelvic endometriosis: histology and clinical significance. *Fertil Steril* 1990;53(6):978–83.
- [68]. Revised American Society for Reproductive Medicine Classification of Endometriosis: 1996. *Fertil Steril* 1997;67(5):817–21.
- [69]. Abrao MS, Podgaec S, Filho BM, Ramos LO, Pinotti JA, de Oliveira RM. The use of biochemical markers in the diagnosis of pelvic endometriosis. *Hum Reprod* 1997;12(11):2523–7.
- [70]. Abrao MS, Podgaec S, Pinotti JA, de Oliveira RM. Tumor markers in endometriosis. *Int J Gynaecol Obstet* 1999;66(1):19–22.
- [71]. Abrao MS, Gonçalves MO, Dias Jr JA, Podgaec S, Chamie LP, Blasbalg R. Comparison between clinical examination, transvaginal sonography and magnetic resonance imaging for the diagnosis of deep endometriosis. *Hum Reprod* 2007;22(12):3092–7.
- [72]. Bazot M, Bornier C, Dubernard G, Roseau G, Cortez A, Daraï E. Accuracy of magnetic resonance imaging and rectal endoscopic sonography for the prediction of location of deep pelvic endometriosis. *Hum Reprod* 2007;22(5):1457–63.
- [73]. Pickett M, Chopin N, Dousset B, Millischer-Bellaische AE, Roseau G, Leconte M, et al. Preoperative work-up for patients with deeply infiltrating endometriosis: transvaginal ultrasonography must definitely be the first-line imaging examination. *Hum Reprod* 2009;24(3):602–7.
- [74]. Yap C, Furness S, Farquhar C. Pre and post operative medical therapy for endometriosis surgery. *Cochrane Database Syst Rev* 2004(3):CD003678.
- [75]. Bukar M, Mustapha Z, Takai UI, Tahir A. Hysterosalpingographic findings in infertile women: a seven year review. *Niger J Clin Pract* 2011;14(2):168–70.
- [76]. Hwang K, Lipshultz LI, Lamb DJ. Use of diagnostic testing to detect infertility. *Curr Urol Rep* 2011;12(1):68–76.
- [77]. Hughes E, Brown J, Collins JJ, Farquhar C, Fedorkow DM, Vandekerckhove P. Ovulation suppression for endometriosis. *Cochrane Database Syst Rev* 2007(3):CD000155.
- [78]. Kennedy S, Bergqvist A, Chapron C, D’Hooghe T, Dunselman G, Greb R, et al. ESHRE guideline for the diagnosis and treatment of endometriosis. *Hum Reprod* 2005;20(10):2698–704.
- [79]. Jacobson TZ, Duffy JM, Barlow D, Farquhar C, Koninckx PR, Olive D. Laparoscopic surgery for subfertility associated with endometriosis. *Cochrane Database Syst Rev* 2010(1):CD001398.
- [80]. Beretta P, Franchi M, Ghezzi F, Busacca M, Zupi E, Bolis P. Randomized clinical trial of two laparoscopic treatments of endometriomas: cystectomy versus drainage and coagulation. *Fertil Steril* 1998;70(6):1176–80.
- [81]. Vercellini P, Somigliana E, Viganò P, Abbiati A, Barbara G, Crosignani PG. Surgery for endometriosis-associated infertility: a pragmatic approach. *Hum Reprod* 2009;24(2):254–69.
- [82]. Bianchi PH, Pereira RM, Zanatta A, Alegretti JR, Motta EL, Serafini PC. Extensive excision of deep infiltrative endometriosis before in vitro fertilization significantly improves pregnancy rates. *J Minim Invasive Gynecol* 2009;16(2):174–80.
- [83]. Daraï E, Lesieur B, Dubernard G, Rouzier R, Bazot M, Ballester M. Fertility after colorectal resection for endometriosis: results of a prospective study comparing laparoscopy with open surgery. *Fertil Steril* 2011;95(6):1903–8.
- [84]. Muzii L, Sereni MI, Cafà EV, Damiani P, Montera R, Zullo MA, et al. Intraoperative three-dimensional ultrasound for hysteroscopic metroplasty: a controlled study. *J Minim Invasive Gynecol* 2011;18(6 Suppl.):S80.
- [85]. Wallach EE, Vlahos NF. Uterine myomas: an overview of development, clinical features, and management. *Obstet Gynecol* 2004;104(2):393–406.
- [86]. Taylor E, Gomel V. The uterus and fertility. *Fertil Steril* 2008;89(1):1–16.

- [87]. Practice Committee of American Society for Reproductive Medicine in collaboration with Society of Reproductive Surgeons. Myomas and reproductive function. *Fertil Steril* 2008;90(5 Suppl.):S125–30.
- [88]. Englund K, Blanck A, Gustavsson I, Lundkvist U, Sjöblom P, Norgren A, et al. Sex steroid receptors in human myometrium and fibroids: changes during the menstrual cycle and onadotropin-releasing hormone treatment. *J Clin Endocrinol Metab* 1998;83(11):4092–6.
- [89]. Nisolle M, Gillerot S, Casanas-Roux F, Squifflet J, Berliere M, Donnez J. Immunohistochemical study of the proliferation index, oestrogen receptors and progesterone receptors A and B in leiomyomata and normal myometrium during the menstrual cycle and under gonadotrophin-releasing hormone agonist therapy. *Hum Reprod* 1999;14(11):2844–50.
- [90]. Garcia CR, Tureck RW. Submucosal leiomyomas and infertility. *Fertil Steril* 1984;42(1):16–9.
- [91]. Goldenberg M, Sivan E, Sharabi Z, Bider D, Rabinovici J, Seidman DS. Outcome of hysteroscopic resection of submucous myomas for infertility. *Fertil Steril* 1995;64(4):714–6.
- [92]. Fernandez H, Sefrioui O, Virelizier C, Gervaise A, Gomel V, Frydman R. Hysteroscopic resection of submucosal myomas in patients with infertility. *Hum Reprod* 2001;16(7):1489–92.
- [93]. Muzii L, Boni T, Bellati F, Marana R, Ruggiero A, Zullo MA, et al. GnRH analogue treatment before hysteroscopic resection of submucous myomas: a prospective, randomized, multicenter study. *Fertil Steril* 2010;94(4):1496–9.
- [94]. Kodaman PH, Arici A. Intra-uterine adhesions and fertility outcome: how to optimize success? *Curr Opin Obstet Gynecol* 2007;19(3):207–14.
- [95]. Yu D, Li TC, Xia E, Huang X, Liu Y, Peng X. Factors affecting reproductive outcome of hysteroscopic adhesiolysis for Asherman's syndrome. *Fertil Steril* 2008;89(3):715–22.
- [96]. Westendorp IC, Ankum WM, Mol BW, Vonk J. Prevalence of Asherman's syndrome after secondary removal of placental remnants or a repeat curettage for incomplete abortion. *Hum Reprod* 1998;13(12):3347–50.
- [97]. Berman JM. Intrauterine adhesions. *Semin Reprod Med* 2008;26(4):349–55.
- [98]. Zikopoulos KA, Kolibianakis EM, Platteau P, de Munck L, Tournaye H, Devroey P, et al. Live delivery rates in subfertile women with Asherman's syndrome after hysteroscopic adhesiolysis using the resectoscope or the Versapoint system. *Reprod Biomed Online* 2004;8(6):720–5.
- [99]. Yasmin H, Nasir A, Noorani KJ. Hysteroscopic management of Ashermans syndrome. *J Pak Med Assoc* 2007;57(11):553–5.
- [100]. Pabuccu R, Onalan G, Kaya C, Selam B, Ceyhan T, Ornek T, et al. Efficiency and pregnancy outcome of serial intrauterine device-guided hysteroscopic adhesiolysis of intrauterine synechiae. *Fertil Steril* 2008;90(5):1973–7.